Results 211 to 220 of about 277,103 (274)

Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis. [PDF]

Front Immunol
Sala I, Pagan E, Pala L, Oriecuia C, Musca M, Specchia C, De Pas T, Cortes J, Giaccone G, Postow M, Gelber RD, Bagnardi V, Conforti F.   +12 more
europepmc   +1 more source

Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials. [PDF]

BMC Med Res Methodol
Collier W, Haaland B, Inker LA, Heerspink HJL, Greene T.   +4 more
europepmc   +1 more source

Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. [PDF]

Sci Rep
Huang L, Kang D, Zhao C, Liu X.
europepmc   +1 more source

Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration.

BMJ
Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartsson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O.   +35 more
europepmc   +1 more source

Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration.

BMJ
Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartsson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O.   +35 more
europepmc   +1 more source

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials

EClinicalMedicine, 2023
Background Interventional trials that evaluate treatment effects using surrogate endpoints have become increasingly common. This paper describes four linked empirical studies and the development of a framework for defining, interpreting and reporting ...
Luca Bertolaccini, Asbjørn Hróbjartsson   +1 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Challenge of Surrogate Endpoints

Southern Medical Journal, 2012
Surrogate endpoints are biomarkers that are intended to substitute for clinical endpoints. They have been used to find novel therapeutic targets, improve the statistical power and shorten the duration of clinical trials, and control the cost of conducting research studies.
James L, Furgerson, William N, Hannah, Jennifer C, Thompson   +2 more
openaire   +2 more sources

True endpoint reduction by surrogate endpoints

Communications in Statistics - Simulation and Computation, 2016
ABSTRACTThe use of surrogate endpoint, which is becoming widely popular now a days, was introduced in medical research to reduce the time of experiment required for the approval of a drug. Through cost cutting and time saving, the surrogate endpoints can bring profit to the medicine producers. We obtain the expression for the reduction of true samples,
Buddhananda Banerjee, Atanu Biswas
openaire   +2 more sources